A Double-Blind, Randomized, Parallel Group, Multi-Centre Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Subjects with Overactive Bladder (OAB) Treated with Antimuscarinics and Dissatisfied due to Lack of Efficacy

Trial Profile

A Double-Blind, Randomized, Parallel Group, Multi-Centre Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Subjects with Overactive Bladder (OAB) Treated with Antimuscarinics and Dissatisfied due to Lack of Efficacy

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Sep 2016

At a glance

  • Drugs Mirabegron (Primary) ; Solifenacin
  • Indications Overactive bladder
  • Focus Registrational; Therapeutic Use
  • Acronyms BEYOND
  • Sponsors Astellas Pharma Europe Ltd
  • Most Recent Events

    • 11 Apr 2013 Planned End Date changed from 1 Mar 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.
    • 01 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 07 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top